Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases

Additional individual contributors of the UCDC and the E-IMD consortium

Research output: Contribution to journalArticle

Abstract

BACKGROUND: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts.

AIMS: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs.

METHODS: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases.

RESULTS: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients.

CONCLUSIONS: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilizing differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

Original languageEnglish
Pages (from-to)93-106
Number of pages14
JournalJournal of Inherited Metabolic Disease
Volume42
Issue number1
DOIs
Publication statusPublished - Jan 2019

Fingerprint

Inborn Urea Cycle Disorder
Rare Diseases
Research
Ornithine Carbamoyltransferase Deficiency Disease
Databases
Information Storage and Retrieval
Natural History
Prenatal Diagnosis
Ammonium Compounds
Liver Transplantation
Sample Size
Outcome Assessment (Health Care)
Newborn Infant
Phenotype

Cite this

Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases. / Additional individual contributors of the UCDC and the E-IMD consortium.

In: Journal of Inherited Metabolic Disease, Vol. 42, No. 1, 01.2019, p. 93-106.

Research output: Contribution to journalArticle

@article{ec15f3ed039a405c91d53e38dc6b6e3d,
title = "Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases",
abstract = "BACKGROUND: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts.AIMS: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs.METHODS: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases.RESULTS: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9{\%}) or by high-risk family screening (24.7{\%}), and less often by newborn screening (8.9{\%}) and prenatal testing (3.7{\%}). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients.CONCLUSIONS: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilizing differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.",
author = "{Additional individual contributors of the UCDC and the E-IMD consortium} and Roland Posset and Garbade, {Sven F} and Nikolas Boy and Burlina, {Alberto B} and Carlo Dionisi-Vici and Dries Dobbelaere and Angeles Garcia-Cazorla and {de Lonlay}, Pascale and Teles, {Elisa Le{\~a}o} and Roshni Vara and Mew, {Nicholas Ah} and Batshaw, {Mark L} and Baumgartner, {Matthias R} and McCandless, {Shawn E} and Jennifer Seminara and Marshall Summar and Hoffmann, {Georg F} and Stefan K{\"o}lker and Peter Burgard",
note = "{\circledC} 2018 SSIEM.",
year = "2019",
month = "1",
doi = "10.1002/jimd.12031",
language = "English",
volume = "42",
pages = "93--106",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-A successful strategy for clinical research of rare diseases

AU - Additional individual contributors of the UCDC and the E-IMD consortium

AU - Posset, Roland

AU - Garbade, Sven F

AU - Boy, Nikolas

AU - Burlina, Alberto B

AU - Dionisi-Vici, Carlo

AU - Dobbelaere, Dries

AU - Garcia-Cazorla, Angeles

AU - de Lonlay, Pascale

AU - Teles, Elisa Leão

AU - Vara, Roshni

AU - Mew, Nicholas Ah

AU - Batshaw, Mark L

AU - Baumgartner, Matthias R

AU - McCandless, Shawn E

AU - Seminara, Jennifer

AU - Summar, Marshall

AU - Hoffmann, Georg F

AU - Kölker, Stefan

AU - Burgard, Peter

N1 - © 2018 SSIEM.

PY - 2019/1

Y1 - 2019/1

N2 - BACKGROUND: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts.AIMS: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs.METHODS: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases.RESULTS: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients.CONCLUSIONS: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilizing differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

AB - BACKGROUND: To improve our understanding of urea cycle disorders (UCDs) prospectively followed by two North American (NA) and European (EU) patient cohorts.AIMS: Description of the NA and EU patient samples and investigation of the prospects of combined and comparative analyses for individuals with UCDs.METHODS: Retrieval and comparison of the data from 1095 individuals (NA: 620, EU: 475) from two electronic databases.RESULTS: The proportion of females with ornithine transcarbamylase deficiency (fOTC-D), particularly those being asymptomatic (asfOTC-D), was higher in the NA than in the EU sample. Exclusion of asfOTC-D resulted in similar distributions in both samples. The mean age at first symptoms was higher in NA than in EU patients with late onset (LO), but similar for those with early (≤ 28 days) onset (EO) of symptoms. Also, the mean age at diagnosis and diagnostic delay for EO and LO patients were similar in the NA and EU cohorts. In most patients (including fOTC-D), diagnosis was made after the onset of symptoms (59.9%) or by high-risk family screening (24.7%), and less often by newborn screening (8.9%) and prenatal testing (3.7%). Analysis of clinical phenotypes revealed that EO patients presented with more symptoms than LO individuals, but that numbers of symptoms correlated with plasma ammonium concentrations in EO patients only. Liver transplantation was reported for 90 NA and 25 EU patients.CONCLUSIONS: Combined analysis of databases drawn from distinct populations opens the possibility to increase sample sizes for natural history questions, while comparative analysis utilizing differences in approach to treatment can evaluate therapeutic options and enhance long-term outcome studies.

U2 - 10.1002/jimd.12031

DO - 10.1002/jimd.12031

M3 - Article

C2 - 30740724

VL - 42

SP - 93

EP - 106

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 1

ER -